APA

Cufer T., Vrdoljak E., Gaafar R., Erensoy I. & Pemberton K. (20070116). Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. : Anti-cancer drugs.

Chicago

Cufer Tanja, Vrdoljak Eduard, Gaafar Rabab, Erensoy Inci and Pemberton Kristine. 20070116. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. : Anti-cancer drugs.

Harvard

Cufer T., Vrdoljak E., Gaafar R., Erensoy I. and Pemberton K. (20070116). Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. : Anti-cancer drugs.

MLA

Cufer Tanja, Vrdoljak Eduard, Gaafar Rabab, Erensoy Inci and Pemberton Kristine. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. : Anti-cancer drugs. 20070116.